AC Immune Ltd (ACIU)vsModerna Inc (MRNA)
ACIU
AC Immune Ltd
$2.63
-1.87%
HEALTHCARE · Cap: $274.42M
MRNA
Moderna Inc
$154.04
-2.55%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 12625% more annual revenue ($2.23B vs $17.51M). MRNA leads profitability with a -141.4% profit margin vs -246.5%. ACIU earns a higher WallStSmart Score of 24/100 (F).
ACIU
Avoid24
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACIU.
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$154.04
$19.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1057.0% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -210.0% — below average capital efficiency
Trading at 9.1x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ACIU
The strongest argument for ACIU centers on Revenue Growth, Debt/Equity. Revenue growth of 1057.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ACIU
The primary concerns for ACIU are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ACIU profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
ACIU carries more volatility with a beta of 1.59 — expect wider price swings.
ACIU is growing revenue faster at 1057.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ACIU scores higher overall (24/100 vs 21/100) and 1057.0% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AC Immune Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company is headquartered in Lausanne, Switzerland.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?